DK1685243T3 - Immortaliserede fuglecellelinjer til virusproduktion - Google Patents
Immortaliserede fuglecellelinjer til virusproduktionInfo
- Publication number
- DK1685243T3 DK1685243T3 DK04798154T DK04798154T DK1685243T3 DK 1685243 T3 DK1685243 T3 DK 1685243T3 DK 04798154 T DK04798154 T DK 04798154T DK 04798154 T DK04798154 T DK 04798154T DK 1685243 T3 DK1685243 T3 DK 1685243T3
- Authority
- DK
- Denmark
- Prior art keywords
- cell lines
- immortalized
- virus production
- bird cell
- production
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title abstract 3
- 229960000074 biopharmaceutical Drugs 0.000 abstract 2
- 238000002255 vaccination Methods 0.000 abstract 2
- 241000271566 Aves Species 0.000 abstract 1
- 108050002653 Retinoblastoma protein Proteins 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0091—Purification or manufacturing processes for gene therapy compositions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
- C12N2710/10222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
- C12N2710/10251—Methods of production or purification of viral material
- C12N2710/10252—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10351—Methods of production or purification of viral material
- C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Manufacturing & Machinery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Developmental Biology & Embryology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03025158A EP1528101A1 (en) | 2003-11-03 | 2003-11-03 | Immortalized avian cell lines for virus production |
PCT/EP2004/052789 WO2005042728A2 (en) | 2003-11-03 | 2004-11-03 | Immortalized avian cell lines for virus production |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1685243T3 true DK1685243T3 (da) | 2008-10-20 |
Family
ID=34400514
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK04798154T DK1685243T3 (da) | 2003-11-03 | 2004-11-03 | Immortaliserede fuglecellelinjer til virusproduktion |
DK08101999.4T DK1939281T4 (da) | 2003-11-03 | 2004-11-03 | Immortaliserede andecellelinjer til virusproduktion |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK08101999.4T DK1939281T4 (da) | 2003-11-03 | 2004-11-03 | Immortaliserede andecellelinjer til virusproduktion |
Country Status (18)
Country | Link |
---|---|
US (2) | US8940534B2 (da) |
EP (4) | EP1528101A1 (da) |
JP (1) | JP4658953B2 (da) |
KR (1) | KR101027755B1 (da) |
CN (1) | CN1934243B (da) |
AT (2) | ATE398672T1 (da) |
AU (1) | AU2004285089B2 (da) |
BR (1) | BRPI0415622B8 (da) |
CA (1) | CA2544462C (da) |
CY (1) | CY1110272T1 (da) |
DE (2) | DE602004014526D1 (da) |
DK (2) | DK1685243T3 (da) |
ES (1) | ES2309578T3 (da) |
PL (1) | PL1685243T3 (da) |
PT (1) | PT1685243E (da) |
RU (1) | RU2359999C2 (da) |
SI (1) | SI1685243T1 (da) |
WO (1) | WO2005042728A2 (da) |
Families Citing this family (129)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004257939B2 (en) * | 2003-07-22 | 2008-06-05 | Valneva | Production of poxviruses with adherent or non adherent avian cell lines |
PT1789084E (pt) | 2004-09-09 | 2011-02-22 | Novartis Vaccines & Diagnostic | Redução de riscos iatrogénicos pontenciais associados às vacinas contra a gripe |
PL1951296T5 (pl) | 2005-11-01 | 2015-06-30 | Seqirus Uk Ltd | Szczepionki wirusowe otrzymane z komórek o niskim poziomie pozostałości DNA komórkowego poprzez traktowanie beta-propiolaktonem |
EP1951298A1 (en) | 2005-11-04 | 2008-08-06 | Novartis Vaccines and Diagnostics S.r.l. | Adjuvanted influenza vaccines including cytokine-inducing agents |
DK1951299T3 (da) | 2005-11-04 | 2012-04-02 | Novartis Vaccines & Diagnostic | Influenzavacciner indeholdende kombinationer af partikelformige adjuvanser og immunforstærkere |
EP1945252B1 (en) | 2005-11-04 | 2013-05-29 | Novartis Vaccines and Diagnostics S.r.l. | Vaccines comprising purified surface antigens prepared from influenza viruses grown in cell culture, adjuvanted with squalene |
CA2628158C (en) | 2005-11-04 | 2015-12-15 | Novartis Vaccines And Diagnostics S.R.L. | Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines |
CA2628206A1 (en) | 2005-11-04 | 2007-05-10 | Novartis Vaccines And Diagnostics S.R.L. | Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant |
EP1783210A1 (en) * | 2005-11-08 | 2007-05-09 | ProBioGen AG | Productivity augmenting protein factors, novel cell lines and uses thereof |
ES2619160T7 (es) | 2006-01-27 | 2020-07-29 | Seqirus Uk Ltd | Vacunas contra la gripe que contienen hemaglutinina y proteínas de la matriz |
CN101448523A (zh) | 2006-03-24 | 2009-06-03 | 诺华疫苗和诊断有限两合公司 | 无需冷藏储存流感疫苗 |
GB0614460D0 (en) | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
EP2497495B3 (en) | 2006-09-11 | 2021-02-17 | Seqirus UK Limited | Making influenza virus vaccines without using eggs |
US20110045022A1 (en) | 2006-12-06 | 2011-02-24 | Theodore Tsai | Vaccines including antigen from four strains of influenza virus |
EP1985305A1 (en) * | 2007-04-24 | 2008-10-29 | Vivalis | Duck embryonic derived stem cell lines for the production of viral vaccines |
CA2692200A1 (en) | 2007-06-27 | 2008-12-31 | Novartis Ag | Low-additive influenza vaccines |
US8357531B2 (en) | 2007-07-03 | 2013-01-22 | Transgene S.A. | Immortalized avian cell lines |
AU2008270317B2 (en) * | 2007-07-03 | 2013-12-05 | Transgene S.A. | Immortalized avian cell lines |
GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
US8685654B2 (en) | 2007-12-24 | 2014-04-01 | Novartis Ag | Assays for adsorbed influenza vaccines |
JP5653223B2 (ja) * | 2008-02-25 | 2015-01-14 | バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated | 連続細胞系の生成方法 |
WO2009109377A1 (en) | 2008-03-04 | 2009-09-11 | Probiogen Ag | Cell line from rousettus as host cell for pathogen amplification |
EP2098590A1 (en) | 2008-03-04 | 2009-09-09 | ProBioGen AG | Cell line from Rousettus as host cell for pathogen amplification |
CN101998990B (zh) | 2008-03-18 | 2013-11-27 | 诺华股份有限公司 | 流感病毒疫苗抗原制备方法的改进 |
EP2310494A1 (en) * | 2008-06-25 | 2011-04-20 | ProBioGen AG | Cell line for propagation of highly attenuated alphaviruses |
EP2199385A1 (en) | 2008-12-16 | 2010-06-23 | ProBioGen AG | Specific and persistent activation of heat shock response in cell lines using a viral factor |
WO2010079081A1 (en) | 2009-01-07 | 2010-07-15 | Glaxosmithkline Biologicals S.A. | Methods for recovering a virus or a viral antigen produced by cell culture |
JP5843615B2 (ja) | 2009-02-06 | 2016-01-13 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 密度勾配超遠心分離によるウイルスまたはウイルス抗原の精製 |
CN105727281A (zh) | 2009-02-10 | 2016-07-06 | 诺华股份有限公司 | 具有减少量的角鲨烯的流感疫苗 |
CA2752041A1 (en) | 2009-02-10 | 2010-08-19 | Novartis Ag | Influenza vaccines with increased amounts of h3 antigen |
SI2396030T1 (sl) | 2009-02-10 | 2015-12-31 | Novartis Ag | Sheme dajanja cepiva proti gripi za seve, povezane s pandemijo |
FR2949344A1 (fr) | 2009-04-27 | 2011-03-04 | Novartis Ag | Vaccins de protection contre la grippe |
PL3178490T3 (pl) | 2009-07-15 | 2022-08-01 | Glaxosmithkline Biologicals S.A. | Kompozycje białka f rsv i sposoby ich wytwarzania |
JP2013504556A (ja) | 2009-09-10 | 2013-02-07 | ノバルティス アーゲー | 気道疾患に対する組み合わせワクチン |
JP5688373B2 (ja) * | 2009-09-30 | 2015-03-25 | 国立大学法人帯広畜産大学 | α−ガラクトースエピトープを発現するトランスジェニック鳥類、ウイルス及びワクチン |
EP2531592A1 (en) | 2010-02-04 | 2012-12-12 | Vivalis | Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells |
ES2528010T5 (es) | 2010-03-08 | 2018-02-19 | Novartis Ag | Métodos para detectar la presencia de patógenos intracelulares |
JP2013529894A (ja) | 2010-04-07 | 2013-07-25 | ノバルティス アーゲー | パルボウイルスb19のウイルス様粒子を生成するための方法 |
EP2563909A1 (en) | 2010-04-26 | 2013-03-06 | Novartis AG | Improved production of virus replicon particles in packaging cells |
JP6200805B2 (ja) | 2010-05-03 | 2017-09-20 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 新規な方法 |
WO2011138682A2 (en) | 2010-05-06 | 2011-11-10 | Novartis Ag | Organic peroxide compounds for microorganism inactivation |
AU2011254204B2 (en) | 2010-05-21 | 2015-08-20 | Seqirus UK Limited | Influenza virus reassortment method |
KR20130081659A (ko) | 2010-06-01 | 2013-07-17 | 노파르티스 아게 | 인플루엔자 백신 항원의 농축 및 동결건조 |
WO2011151723A2 (en) | 2010-06-01 | 2011-12-08 | Novartis Ag | Concentration of vaccine antigens without lyophilization |
WO2012006293A1 (en) | 2010-07-06 | 2012-01-12 | Novartis Ag | Norovirus derived immunogenic compositions and methods |
ES2531577T3 (es) | 2010-08-20 | 2015-03-17 | Novartis Ag | Conjuntos de agujas para la administración de vacuna soluble contra la gripe |
EP4098324A1 (en) | 2010-10-11 | 2022-12-07 | GlaxoSmithKline Biologicals S.A. | Antigen delivery platforms |
US9453203B2 (en) | 2010-11-02 | 2016-09-27 | Helmholtz-Zentrum Fur Infektionsforschung | Methods and vectors for cell immortalisation |
WO2012095514A1 (en) | 2011-01-14 | 2012-07-19 | Vivalis | Recombinant protein production system |
AU2012211278B2 (en) | 2011-01-26 | 2016-11-10 | Glaxosmithkline Biologicals Sa | RSV immunization regimen |
RS56748B1 (sr) | 2011-05-13 | 2018-03-30 | Glaxosmithkline Biologicals Sa | Pre-fuzioni rsv f antigeni |
EP2724157B1 (en) | 2011-06-27 | 2017-03-08 | Valneva | Method for screening cells |
CA2841047A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic compositions and uses thereof |
CA2840989A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic combination compositions and uses thereof |
US20140271829A1 (en) | 2011-10-11 | 2014-09-18 | Anders Lilja | Recombinant self-replicating polycistronic rna molecules |
US20140348863A1 (en) | 2011-10-12 | 2014-11-27 | Alessia Bianchi | Cmv antigens and uses thereof |
GB201216121D0 (en) | 2012-09-10 | 2012-10-24 | Novartis Ag | Sample quantification by disc centrifugation |
JP2014532620A (ja) | 2011-10-20 | 2014-12-08 | ノバルティス アーゲー | 小児の初回免疫のためのアジュバント添加インフルエンザbウイルスワクチン |
EP2660316A1 (en) | 2012-05-02 | 2013-11-06 | Helmholtz-Zentrum für Infektionsforschung GmbH | Avian cell line and its use in production of protein |
EP2869842A1 (en) | 2012-07-06 | 2015-05-13 | Novartis AG | Immunogenic compositions and uses thereof |
GB201218195D0 (en) | 2012-10-10 | 2012-11-21 | Istituto Zooprofilattico Sperimentale Delle Venezie | Composition |
BR112015011389A2 (pt) | 2012-11-20 | 2017-08-22 | Glaxosmithkline Biologicals Sa | Complexo f do vírus sincicial respiratório, métodos para produzir um complexo f do vírus sincicial respiratório e para indução de uma resposta imunológica a um f de rsv em um indivíduo, e, composição imunogênica |
CN103060376A (zh) * | 2012-12-11 | 2013-04-24 | 上海实验动物研究中心 | 一种禽腺病毒转移载体及其制备方法 |
US20140193484A1 (en) | 2013-01-10 | 2014-07-10 | Sylvie Carine Bertholet Girardin | Influenza virus immunogenic compositions and uses thereof |
US20140255447A1 (en) * | 2013-03-05 | 2014-09-11 | Biomune Company | Production of avian embryo cells |
ES2778928T3 (es) | 2013-08-30 | 2020-08-12 | Glaxosmithkline Biologicals Sa | Producción a gran escala de virus en cultivos celulares |
CN104726409B (zh) * | 2013-12-19 | 2017-12-29 | 普莱柯生物工程股份有限公司 | 一种永生化的鸭胚肝细胞系的制备方法和应用 |
US20150282503A1 (en) * | 2014-04-02 | 2015-10-08 | Synageva Biopharma Corp. | Producing Therapeutic Proteins |
EP2974739A1 (en) | 2014-07-15 | 2016-01-20 | Novartis AG | RSVF trimerization domains |
HUE045108T2 (hu) | 2014-07-16 | 2019-12-30 | Transgene Sa | Onkolitikus vírus immunellenõrzõpont-modulátorok expresszálására |
MX2017007196A (es) | 2014-12-04 | 2017-08-28 | Intervet Int Bv | Fibroblastos de embrion de pollo inmortalizados. |
EP3031822A1 (en) | 2014-12-08 | 2016-06-15 | Novartis AG | Cytomegalovirus antigens |
EP3234113B1 (en) | 2014-12-16 | 2019-01-23 | GlaxoSmithKline Biologicals S.A. | A method for a large scale virus purification |
RU2745567C2 (ru) | 2014-12-17 | 2021-03-29 | Фундасион Пара Ла Инвестигасион Медика Апликада | Конструкции нуклеиновой кислоты и векторы для генотерапии для применения для лечения болезни вильсона и других состояний |
EP3744351A1 (en) | 2014-12-17 | 2020-12-02 | Fundacion para la Investigacion Medica Aplicada | Nucleic acid constructs and gene therapy vectors for use in the treatment of wilson's disease and other conditions |
EP3047856A1 (en) | 2015-01-23 | 2016-07-27 | Novartis AG | Cmv antigens and uses thereof |
WO2016131945A1 (en) | 2015-02-20 | 2016-08-25 | Transgene Sa | Combination product with autophagy modulator |
BR112017028011A2 (pt) | 2015-06-26 | 2018-08-28 | Seqirus Uk Ltd | vacinas de gripe correspondentes antigenicamente |
EP3764098B1 (en) | 2015-07-07 | 2022-11-16 | Seqirus UK Limited | Influenza potency assays |
US20190134190A1 (en) | 2016-05-04 | 2019-05-09 | Transgene Sa | Combination therapy with cpg tlr9 ligand |
WO2018069316A2 (en) | 2016-10-10 | 2018-04-19 | Transgene Sa | Immunotherapeutic product and mdsc modulator combination therapy |
WO2018091680A1 (en) | 2016-11-18 | 2018-05-24 | Transgene Sa | Cowpox-based oncolytic vectors |
CN107012122A (zh) * | 2016-12-12 | 2017-08-04 | 江苏省农业科学院 | 一种永生化鸡胚胎肝细胞系及其制备方法和用途 |
KR20190097240A (ko) | 2016-12-28 | 2019-08-20 | 트랜스진 에스.에이. | 종양용해성 바이러스 및 치료 분자 |
CA3057171A1 (en) | 2017-03-30 | 2018-10-04 | The University Of Queensland | Chimeric polypeptides containing virus fusion ectodomain and complementary heptad repeats and uses thereof |
EP3641803A2 (en) | 2017-06-21 | 2020-04-29 | Transgene | Personalized vaccine |
WO2019020543A1 (en) | 2017-07-28 | 2019-01-31 | Transgene Sa | ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS |
EP3687561A4 (en) | 2017-09-01 | 2021-06-09 | The Australian National University | IMMUN REGULATORY MOLECULES AND THEIR USES |
AU2018359420A1 (en) | 2017-10-31 | 2020-06-04 | Kalivir Immunotherapeutics, Inc. | Platform oncolytic vector for systemic delivery |
WO2019092002A1 (en) | 2017-11-07 | 2019-05-16 | Valneva Se | Pharmaceutical compositions for treatment or prevention of viral infections |
SG11202004926WA (en) | 2017-12-01 | 2020-06-29 | Encoded Therapeutics Inc | Engineered dna binding proteins |
US20210180084A1 (en) | 2018-05-14 | 2021-06-17 | Vivet Therapeutics | Gene therapy vectors comprising s/mar sequences |
WO2020011754A1 (en) | 2018-07-09 | 2020-01-16 | Transgene | Chimeric vaccinia viruses |
WO2020012037A1 (en) | 2018-07-13 | 2020-01-16 | Valneva Se | Method for rescuing and producing a virus in avian cells |
EP3617230A1 (en) | 2018-09-03 | 2020-03-04 | BioInvent International AB | Novel antibodies and nucleotide sequences, and uses thereof |
CN110396496B (zh) * | 2018-09-30 | 2023-06-20 | 湖北省农业科学院畜牧兽医研究所 | 一种鸭小肠上皮细胞的培养方法及应用 |
SG11202103681UA (en) | 2018-10-12 | 2021-05-28 | Vivet Therapeutics | Codon-optimized transgene for the treatment of progressive familiar intrahepatic cholestasis type 3 (pfic3) |
CN109321516A (zh) * | 2018-11-07 | 2019-02-12 | 贵州大学 | 一种鸭原代肝细胞分离及培养方法 |
WO2020094693A1 (en) | 2018-11-07 | 2020-05-14 | Vivet Therapeutics | Codon-optimized abcb11 transgene for the treatment of progressive familial intrahepatic cholestasis type 2 (pfic2) |
EP4257155A3 (en) | 2018-11-16 | 2024-02-28 | Encoded Therapeutics, Inc. | Compositions and methods for treating wilson's disease |
SG11202104869SA (en) | 2018-11-23 | 2021-06-29 | Valneva Se | Food products comprising avian stem cells |
CN113453712A (zh) | 2018-12-28 | 2021-09-28 | 特兰斯吉恩股份有限公司 | M2缺陷型痘病毒 |
EP3686276A1 (en) * | 2019-01-28 | 2020-07-29 | Freie Universität Berlin | Production of viruses in continuously growing epithelial cell lines derived from chicken gut |
EP3993871A1 (en) | 2019-07-02 | 2022-05-11 | Fundacion para la Investigacion Medica Aplicada | Cpla2e inducing agents and uses thereof |
CA3146900A1 (en) | 2019-07-21 | 2021-01-28 | Glaxosmithkline Biologicals Sa | Therapeutic viral vaccine |
WO2021014385A1 (en) | 2019-07-24 | 2021-01-28 | Glaxosmithkline Biologicals Sa | Modified human cytomegalovirus proteins |
AU2020389047A1 (en) | 2019-11-18 | 2022-06-02 | Seqirus Pty Ltd. | Method for producing reassortant influenza viruses |
US20210315986A1 (en) | 2020-04-13 | 2021-10-14 | Janssen Biotech, Inc. | Psma and steap1 vaccines and their uses |
EP4178605A1 (en) | 2020-07-13 | 2023-05-17 | Transgene | Treatment of immune depression |
EP4192961A2 (en) | 2020-08-06 | 2023-06-14 | Fundacion para la Investigacion Medica Aplicada | Viral particles for use in treating tauopathies such as alzheimer's diseases by gene therapy |
US20230265456A1 (en) | 2020-08-10 | 2023-08-24 | Fundacion Para La Investigacion Medica Aplicada | Gene therapy vector expressing cyp27a1 for the treatment of cerebrotendinous xanthomatosis |
CA3195052A1 (en) | 2020-10-09 | 2022-04-14 | UCB Biopharma SRL | Nucleic acid constructs, viral vectors and viral particles |
EP4267197A1 (en) | 2020-12-23 | 2023-11-01 | Vivet Therapeutics | Minimal bile acid inducible promoters for gene therapy |
WO2022148736A1 (en) | 2021-01-05 | 2022-07-14 | Transgene | Vectorization of muc1 t cell engager |
JP2024502377A (ja) | 2021-01-10 | 2024-01-18 | スーパーミート ザ エッセンス オブ ミート リミテッド | 培養肉産業用の多能性幹細胞凝集体及びそれから得られる微小組織 |
EP4032547A1 (en) | 2021-01-20 | 2022-07-27 | GlaxoSmithKline Biologicals S.A. | Hsv1 fce derived fragements for the treatment of hsv |
MX2023012608A (es) | 2021-04-30 | 2023-11-03 | Kalivir Immunotherapeutics Inc | Virus oncoliticos para la expresion modificada del mhc. |
WO2023025899A2 (en) | 2021-08-26 | 2023-03-02 | Transgene | Delivery system for targeting genes of the interferon pathway |
TW202321458A (zh) | 2021-09-22 | 2023-06-01 | 瑞典商生物創新國際公司 | 新穎抗體組合及其用途 |
EP4419650A1 (en) | 2021-10-18 | 2024-08-28 | Supermeat the Essence of Meat Ltd. | Methods for preparing a food ingredient and compositions produced thereby |
CN118434876A (zh) | 2021-10-28 | 2024-08-02 | Ucb生物制药有限责任公司 | 核酸构建体、病毒载体和病毒颗粒 |
CN114350601B (zh) * | 2021-12-21 | 2022-12-27 | 广东省华晟生物技术有限公司 | 樱桃谷鸭成纤维细胞系及其构建方法与应用 |
WO2023144665A1 (en) | 2022-01-28 | 2023-08-03 | Glaxosmithkline Biologicals Sa | Modified human cytomegalovirus proteins |
CN114908053A (zh) * | 2022-04-24 | 2022-08-16 | 上海交通大学 | 孔雀成纤维永生化细胞系的制备方法及其在病毒扩增中的应用 |
WO2023213763A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab |
WO2023213764A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf |
WO2024003353A1 (en) | 2022-07-01 | 2024-01-04 | Transgene | Fusion protein comprising a surfactant-protein-d and a member of the tnfsf |
WO2024038175A1 (en) | 2022-08-18 | 2024-02-22 | Transgene | Chimeric poxviruses |
CN116496992B (zh) * | 2023-04-24 | 2023-12-01 | 江苏省家禽科学研究所 | 一种鸡胚成肌永生化细胞及其构建方法和应用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997000326A1 (en) * | 1995-06-15 | 1997-01-03 | Introgene B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
KR970010968A (ko) | 1995-08-24 | 1997-03-27 | 윤원영 | 오리 배 세포를 이용한 에리스로포이틴의 발현 시스템 |
US5989805A (en) | 1995-10-27 | 1999-11-23 | Board Of Trustees Operating Michigan State University | Immortal avian cell line to grow avian and animal viruses to produce vaccines |
FR2749022B1 (fr) | 1996-05-23 | 2001-06-01 | Rhone Merieux | Cellules aviaires immortelles |
US5830723A (en) | 1996-08-13 | 1998-11-03 | Regents Of The University Of Minnesota | Method for immortalizing chicken cells |
US5672485A (en) | 1996-08-13 | 1997-09-30 | Regents Of The University Of Minnesota | Immortalized cell lines for virus growth |
FR2767335B1 (fr) | 1997-08-14 | 2001-09-28 | Ct Nat D Etudes Veterinaires E | Adenovirus aviaire celo recombinant comme vecteur vaccinant |
DE19955558C2 (de) * | 1999-11-18 | 2003-03-20 | Stefan Kochanek | Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren |
US7192759B1 (en) * | 1999-11-26 | 2007-03-20 | Crucell Holland B.V. | Production of vaccines |
CN1139655C (zh) * | 2001-08-23 | 2004-02-25 | 北京大学人民医院 | 一种人卵巢癌永生化细胞株及其建立方法 |
CA2489301A1 (en) | 2002-08-07 | 2004-02-19 | Bavarian Nordic A/S | Vaccinia virus host range genes to increase the titer of avipoxviruses |
MXPA04012966A (es) | 2002-09-05 | 2005-05-16 | Bavarian Nordic As | Metodo para el cultivo de celulas primarias y para la amplificacion de virus bajo condiciones libres de suero. |
AU2004257939B2 (en) | 2003-07-22 | 2008-06-05 | Valneva | Production of poxviruses with adherent or non adherent avian cell lines |
-
2003
- 2003-11-03 EP EP03025158A patent/EP1528101A1/en not_active Withdrawn
-
2004
- 2004-11-03 PT PT04798154T patent/PT1685243E/pt unknown
- 2004-11-03 KR KR1020067010635A patent/KR101027755B1/ko active IP Right Grant
- 2004-11-03 US US10/578,043 patent/US8940534B2/en active Active
- 2004-11-03 EP EP08101999.4A patent/EP1939281B2/en not_active Expired - Lifetime
- 2004-11-03 JP JP2006537316A patent/JP4658953B2/ja not_active Expired - Lifetime
- 2004-11-03 AT AT04798154T patent/ATE398672T1/de active
- 2004-11-03 BR BRPI0415622A patent/BRPI0415622B8/pt active IP Right Grant
- 2004-11-03 CN CN2004800397218A patent/CN1934243B/zh not_active Expired - Lifetime
- 2004-11-03 CA CA2544462A patent/CA2544462C/en not_active Expired - Lifetime
- 2004-11-03 ES ES04798154T patent/ES2309578T3/es not_active Expired - Lifetime
- 2004-11-03 SI SI200430843T patent/SI1685243T1/sl unknown
- 2004-11-03 EP EP10002423A patent/EP2192173A1/en not_active Withdrawn
- 2004-11-03 AT AT08101999T patent/ATE460473T1/de active
- 2004-11-03 EP EP04798154A patent/EP1685243B1/en not_active Expired - Lifetime
- 2004-11-03 DE DE602004014526T patent/DE602004014526D1/de not_active Expired - Lifetime
- 2004-11-03 AU AU2004285089A patent/AU2004285089B2/en not_active Expired
- 2004-11-03 RU RU2006119447/13A patent/RU2359999C2/ru active
- 2004-11-03 DK DK04798154T patent/DK1685243T3/da active
- 2004-11-03 WO PCT/EP2004/052789 patent/WO2005042728A2/en active IP Right Grant
- 2004-11-03 DK DK08101999.4T patent/DK1939281T4/da active
- 2004-11-03 PL PL04798154T patent/PL1685243T3/pl unknown
- 2004-11-03 DE DE602004025996T patent/DE602004025996D1/de not_active Expired - Lifetime
-
2008
- 2008-09-18 CY CY20081101019T patent/CY1110272T1/el unknown
-
2012
- 2012-07-26 US US13/558,567 patent/US20120288916A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1685243T3 (da) | Immortaliserede fuglecellelinjer til virusproduktion | |
ATE466932T1 (de) | Vermehrung von viren in zellkultur | |
WO2007048089A3 (en) | Multi-plasmid system for the production of influenza virus | |
ATE547511T1 (de) | Nichttumorbildende mdck-zellinie zur vermehrung von viren | |
EA200801756A1 (ru) | Противогриппозные вакцины, содержащие гемагглютинин и белки матрикса | |
CY1119106T1 (el) | Αντισωματα εναντι masp-2 | |
EA201200217A1 (ru) | Рнк с комбинацией из немодифицированных и модифицированных нуклеотидов для экспрессии белков | |
BR112013007862A2 (pt) | ácidos nucleicos manipulados e métodos de uso dos mesmos. | |
EA200970996A1 (ru) | Стволовые клеточные линии, полученные из эмбрионов утки, для производства вирусных вакцин | |
EP1697521A4 (en) | PLASMID MULTIPLE SYSTEM FOR PRODUCING INFLUENZA VIRUS | |
NO20062709L (no) | Stamceller som er egnet for transplantasjon, fremstilling derav og farmasoytiske preperater omfattende nevnte stamceller | |
ATE507242T1 (de) | Wirtszellenspezifische bindungsmoleküle, die dazu in der lage sind, viren zu neutralisieren, und anwendungen davon | |
EA201001045A1 (ru) | Модифицированный вирус гриппа | |
AR113492A2 (es) | Furina recombinante libre de proteínas sustancialmente animal y métodos para producirla | |
BRPI0519705A2 (pt) | composiÇÕes, proteÍnas de fusço e mÉtodos de estimular uma resposta imune em um indivÍduo | |
CY1121438T1 (el) | Μεθοδοι για την παρασκευη υδροπηκτων χρησιμοποιωντας ενζυμα λιπασης | |
WO2005115448A3 (en) | Multi plasmid system for the production of influenza virus | |
AR024122A1 (es) | Metodo para la estabilizacion intensificada de proteinas y produccion de lineas celulares que sirven para la produccion de dichas proteinas estabilizadas | |
EP4410970A3 (en) | Efficient cell culture system for hepatitis c virus genotype 6a | |
WO2007019532A3 (en) | Peptide aptamers that bind to the rep proteins of ssdna viruses | |
DK1537204T3 (da) | Granzym B som HSP70/HSP70-peptidafhængig udløser af programmeret celledød hos tumorceller | |
DK1383796T3 (da) | Neurovirulent stamme af viruset West Nile og anvendelser heraf | |
EA201201620A1 (ru) | Способ получения рнк-вируса | |
EA201071226A1 (ru) | Искусственный каркас белка | |
Koh et al. | Expression of hepatitis C virus envelope glycoprotein E2 in transgenic rice cell suspension culture |